St. Jude Medical Announces Launch of OPTIS Mobile System in Europe and Japan
February 08 2016 - 8:00AM
Business Wire
The OPTIS™ Mobile System combines OCT imaging with angiography
to provide hospitals with multiple catheterization labs the
technology to make efficient assessments for more accurate PCI
guidance
St. Jude Medical, Inc. (NYSE:STJ), a global medical device
company, today announced the launch of the company’s OPTIS™ Mobile
System in Japan and Europe. The diagnostic system is designed to
couple state-of-the-art optical coherence tomography (OCT) and
angiography co-registration with fractional flow reserve (FFR)
technology into one portable system for hospitals with multiple
catheterization labs.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160208005638/en/
OPTIS Mobile Integrated Lab (Photo:
Business Wire)
Driven by a global increase in vascular disease and enabled by
advances in technology, the catheterization lab allows physicians
to use minimally invasive percutaneous coronary intervention (PCI)
procedures that give patients an alternative to open heart surgery
with the goal to improve patient outcomes, shorten hospital stays
and reduce hospital costs. The latest OPTIS System offers
physicians an efficient way to optimize PCI procedures for the
treatment of vascular disease by combining diagnostic tools
designed to improve patient outcomes into one portable device.
Utilizing a combination of technology previously available only
in the St. Jude Medical OPTIS Integrated System, the OPTIS Mobile
System is designed to help physicians make improved stenting
decisions based on high-resolution and three dimensional OCT views
of coronary anatomy while simultaneously mapping their exact
location via angiogram. The OPTIS Mobile System also integrates St.
Jude Medical PressureWire™ FFR measurement technology, which offers
physicians detailed coronary hemodynamic (circulatory) information
during PCI. Clinical data has shown the physiological measurements
provided by St. Jude Medical FFR technology can improve outcomes
and reduce health care costs over traditional diagnostic imaging
tools.
“As the interventional cardiology landscape continues to expand,
there is a real need for more portable intravascular imaging
systems to ensure hospitals with multiple catheterization labs have
the right technology available for physicians to make more informed
treatment decisions during PCI,” said Dr. Nick West, Papworth
Hospital, Cambridge, UK. “The imaging advancements offered with the
OPTIS Mobile System provide the same benefits of the OPTIS
Integrated System, and allow physicians to clearly visualize
complex cardiac anatomy and evaluate how to best proceed during
PCI.”
Sometimes referred to as coronary angioplasty, PCI is a
catheter-based procedure designed to open coronary blockages or
plaque buildup and restore blood flow to the heart. Traditionally,
physicians have relied on either angiography or intravascular
ultrasound to guide PCI procedures. St. Jude Medical’s ILUMIEN™
System first combined OCT and FFR technology to enable a more
detailed, physiological and anatomical analysis of blood flow
blockages inside the coronary vessels.
“The OPTIS Mobile System represents the ongoing commitment of
St. Jude Medical to develop products that provide physicians with
more options for improved OCT and angiography co-registration
guidance in their daily practice,” said Dr. Eric Fain, Group
President of St. Jude Medical. “In contrast with intravascular
ultrasound, OCT offers increased resolution and highly-detailed
intracoronary arterial views, which can improve PCI procedures,
especially in complex cases.”
A System Backed by a Strong Research Portfolio
The benefits of utilizing OCT and FFR during PCI are supported
by a robust portfolio of clinical data. The ILUMIEN I and ILUMIEN
II studies have shown that St. Jude Medical’s OCT imaging
technology can influence pre- and post-PCI decision making, stent
sizing and deployment. The St. Jude Medical sponsored FAME body of
evidence demonstrated St. Jude Medical PressureWire FFR measurement
technology can improve patient outcomes and reduce costs in
patients with stable coronary artery disease.
The multicenter ILUMIEN III: OPTIMIZE PCI clinical trial is
currently underway to further develop the body of clinical evidence
supporting OCT technology in relation to first generation imaging
tools.
About Optical Coherence Tomography Imaging
St. Jude Medical’s OCT technology is an intravascular imaging
tool that uses light to provide anatomical images of disease
morphology and automated measurements. With OCT technology,
physicians can visualize and measure important vessel
characteristics that are otherwise not visible or difficult to
assess with the older imaging technology. As a result, OCT can
provide automated, highly accurate measurements that can help guide
stent selection and deployment and assess stent placement to help
ensure successful procedures. This can potentially minimize the
need for repeat revascularization.
About Fractional Flow Reserve (FFR)
FFR is a physiological index used to determine the hemodynamic
severity of narrowings (or lesions) in the coronary arteries, and
is measured using St. Jude Medical PressureWire™ Aeris™ and
PressureWire™ Certus™ systems. FFR specifically identifies which
coronary narrowings are responsible for obstructing the flow of
blood to a patient’s heart muscle (called ischemia), and helps
guide the interventional cardiologist in determining which lesions
warrant stenting, resulting in improved patient outcomes and
reduced health care costs.
About St. Jude Medical
St. Jude Medical is a leading global medical device manufacturer
and is dedicated to transforming the treatment of some of the
world’s most expensive epidemic diseases. The company does this by
developing cost-effective medical technologies that save and
improve lives of patients around the world. Headquartered in St.
Paul, Minn., St. Jude Medical has five major areas of focus that
include heart failure, atrial fibrillation, neuromodulation,
traditional cardiac rhythm management, and cardiovascular diseases.
For more information, please visit sjm.com or follow us on Twitter
@SJM_Media.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. Such forward-looking
statements include the expectations, plans and prospects for the
Company, including potential clinical successes, anticipated
regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made
by the Company are based upon management’s current expectations and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control
and the risk factors and other cautionary statements described in
the Company’s filings with the SEC, including those described in
the Risk Factors and Cautionary Statements sections of the
Company’s Annual Report on Form 10-K for the fiscal year ended
January 3, 2015 and Quarterly Report on Form 10-Q for the fiscal
quarter ended October 3, 2015. The Company does not intend to
update these statements and undertakes no duty to any person to
provide any such update under any circumstance.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160208005638/en/
St. Jude Medical, Inc.J.C. Weigelt, 651 756 4347Investor
Relationsjweigelt@sjm.comLaurel Hood, 651-756-2853Media
Relationslhood02@sjm.com
SJM (NYSE:STJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Apr 2023 to Apr 2024